Phase II Trial of Binimetinib with mFOLFOX6 in Advanced Biliary Tract Cancers
A phase II trial is evaluating the efficacy of binimetinib combined with mFOLFOX6 chemotherapy in patients with advanced biliary tract cancers.
Phase II
National Cancer Institute
Status
Active
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Strategic implication
Success in this trial may enhance the strategic positioning of binimetinib in the oncology portfolio, particularly for advanced biliary tract cancers.
Why it matters
The ongoing phase II trial of binimetinib combined with mFOLFOX6 represents a significant opportunity to enhance treatment options for advanced biliary tract cancers. Success in this trial could strengthen binimetinib's position within the oncology portfolio and influence competitive dynamics in the market.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor trial results and any subsequent regulatory filings or partnerships that may arise from the findings.
Related companies & assets
Assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.